Before your blood test

Do peptides affect blood work — and which labs should you check while using them?

Short answer

Yes — by doing what they do, not by interfering with the assays. GLP-1 drugs (semaglutide, tirzepatide) lower glucose and A1c and can raise lipase; growth-hormone secretagogues (ipamorelin, CJC-1295, MK-677) raise IGF-1 and can push glucose up; BPC-157 and TB-500 have no known lab signature. Don't stop a prescribed peptide for a draw — fast 8–12 hours and note your last dose time.

Medically reviewed by Youmna DiStefano, MD · Last reviewed September 2026

Which results does it affect?

Marker	Direction	How long	What to do
Fasting glucose, hemoglobin A1c	lowers	While on a GLP-1 (semaglutide, tirzepatide); A1c reflects the prior ~3 months	Expected treatment effect — A1c is the monitoring marker, not a reason to stop [source]
Lipase, amylase	can raise	While on a GLP-1	Small rises are common; a marked rise with abdominal pain needs prompt medical attention (pancreatitis is a labeled warning) [source]
Creatinine, BUN (kidney function)	can raise	During GLP-1 nausea/vomiting spells	Usually dehydration; hydrate before the draw and flag recent GI symptoms [source]
IGF-1	raises	While on growth-hormone secretagogues (ipamorelin, CJC-1295, sermorelin, tesamorelin, MK-677)	The marker that shows the peptide is working — and the one to keep inside the age-adjusted reference range [source]
Fasting glucose, A1c, fasting insulin	can raise	While on growth-hormone secretagogues, most reported with MK-677	Growth hormone opposes insulin; check glucose or A1c alongside IGF-1 [source]
Testosterone, estradiol, hematocrit	raises or lowers	Only when peptides are stacked with TRT or an aromatase inhibitor	Monitor as for TRT: total/free testosterone, estradiol, CBC (hematocrit), PSA if over 40 [source]
CMP, CBC, lipid panel	interferes	BPC-157, TB-500, GHK-Cu: no human trial data, no known lab signature	Baseline safety labs before and 8–12 weeks into use; compounded versions are unapproved (FDA) [source]

Which peptides change which labs?

The word "peptide" covers three very different groups. GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are FDA-approved drugs with a well-documented lab footprint: fasting glucose and A1c fall, triglycerides usually improve with weight loss, lipase and amylase can drift up, and kidney markers can rise transiently when nausea or vomiting leads to dehydration. Compounded versions carry the same pharmacology plus the dosing and quality concerns the FDA has flagged.

Growth-hormone secretagogues — ipamorelin, CJC-1295, sermorelin, tesamorelin, the GHRPs and the oral ibutamoren (MK-677) — push the pituitary to release growth hormone, and the liver responds by making more IGF-1. IGF-1 is stable across the day, which is why it, rather than growth hormone itself, is the monitoring marker. Because growth hormone opposes insulin, fasting glucose, insulin and A1c can climb — the trade-off these protocols need to watch.

"Repair" peptides — BPC-157, TB-500 (thymosin beta-4 fragment), GHK-Cu and similar — have no human clinical trials and no established lab signature. In 2023 the FDA placed BPC-157, CJC-1295, ipamorelin, ibutamoren, AOD-9604 and several GHRPs on its list of bulk substances that may present significant safety risks in compounding, which means there is no approved product and no labeled monitoring. Labs here are baseline safety (CMP, CBC, lipids) rather than efficacy.

What to check before and during peptide use

A sensible baseline before starting anything: CMP (liver and kidney function, glucose), CBC, lipid panel, hemoglobin A1c and fasting insulin, plus the hormone panel relevant to the protocol. On a GLP-1, the follow-up set is A1c or fasting glucose, lipase, a CMP and lipids. On a growth-hormone secretagogue it is IGF-1 with fasting glucose or A1c, repeated 8–12 weeks after any change. Anyone stacking peptides with testosterone should monitor as for TRT — total and free testosterone, estradiol, hematocrit and, over 40, PSA.

TestWell's Peptide Therapy Monitoring Panel bundles IGF-1, fasting insulin, A1c, CMP, CBC with differential, lipid panel, thyroid (TSH, free T3, free T4), testosterone (free and total) with SHBG, estradiol, DHEA-S, AM cortisol, hs-CRP, ferritin and iron, B12 and vitamin D — the baseline and follow-up set in one draw. Lipase is a separate add-on for GLP-1 users.

How to prepare for the draw

Fast 8–12 hours with water only, because fasting glucose, fasting insulin and the lipid panel are in the set. Keep taking prescribed medications, including a GLP-1, on the usual schedule — stopping distorts exactly what the labs are meant to show. Write down the last dose time of anything injectable so the clinician can read the result in context, and drink water beforehand: GLP-1 nausea plus a fasting morning is the classic recipe for a falsely high creatinine.

Common questions

Will peptides show up on a blood test?

Not on routine chemistry. A CMP or hormone panel cannot detect BPC-157 or ipamorelin — those require specialized mass-spectrometry methods used by anti-doping laboratories. What routine labs show is the effect: a higher IGF-1 on a growth-hormone secretagogue, a lower A1c on a GLP-1.

Should I stop peptides before blood work?

No — monitoring labs are meant to show the peptide's effect, and a prescribed GLP-1 should never be stopped without the prescriber. Fast 8–12 hours, keep your usual schedule and note your last dose time.

Which labs matter most on semaglutide or tirzepatide?

A1c or fasting glucose (the treatment effect), lipase (the pancreatitis warning), a CMP for kidney function and hydration, and a lipid panel. If you also take insulin or a sulfonylurea, low blood sugar is the interaction to watch for.

What IGF-1 level is right on ipamorelin or CJC-1295?

There is no universal target. IGF-1 is read against an age-adjusted reference range; a result above that range is a reason to talk to the prescriber, because sustained growth-hormone excess raises glucose and has long-term risks. This page does not give dosing guidance.

Sources

Educational content, not a diagnosis. Lab results are one input; a clinician interprets them with your history and exam.